491 completed. 491 Phase 2, 33 Phase 3, 29 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 491 | Completed 491 |
| Phase 3 | 33 | Completed 33 |
| Phase 1 | 29 | Completed 29 |
Follow Asthma: new trials by email Literature Review of Asthma trials Research Report on Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide and Formoterol Fumarate, Placebo for CP006 Inhalation Powder - Asthma | Phase 2 | Completed | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | 150 | 2025-11-21 | 2026-09-08 |
| Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) Rademikibart in prefilled syringe, Matching placebo in prefilled syringe - Asthma Acute | Phase 2 | Completed | Connect Biopharm LLC | 160 | 2025-08-08 | 2026-09-16 |
| Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge ETH47, Placebo - Asthma (Diagnosis) | Phase 2 | Completed | Ethris GmbH | 50 | 2025-06-24 | 2026-11-03 |
| A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001 CHF 6001 - Asthma | Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 50 | 2025-03-28 | 2025-11-26 |
| A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI - Asthma | Phase 2 | Completed | AstraZeneca | 118 | 2025-02-10 | 2026-08-27 |
| A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations AZD8630, Placebo, Inhaler - Asthma | Phase 2 | Completed | AstraZeneca | 537 | 2024-08-30 | 2026-03-02 |
| Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma AZD4604, Placebo to AZD4604 - Asthma | Phase 2 | Completed | AstraZeneca | 36 | 2024-08-05 | 2025-10-23 |
| A Study to Evaluate Solriktug in Adult Participants With Asthma NSI-8226, Placebo - Asthma | Phase 2 | Completed | Uniquity One (UNI) | 145 | 2024-07-26 | 2026-10-28 |
| A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) Verekitug (UPB-101), Placebo - Severe Asthma | Phase 2 | Completed | Upstream Bio Inc. | 479 | 2024-02-27 | 2026-05-01 |
| Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA AZD4604, Placebo - Asthma | Phase 2 | Completed | AstraZeneca | 339 | 2023-11-16 | 2025-11-13 |
| Treating Exacerbations of Asthma With Oral Montelukast in Children Montelukast Oral Granules, Albuterol, Corticosteroid - Status Asthmaticus | Phase 2 | Completed | Vanderbilt University Medical Center | 90 | 2023-10-20 | 2026-07-02 |
| Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma Lunsekimig, Placebo - Asthma | Phase 2 | Completed | Sanofi | 685 | 2023-10-16 | 2026-03-17 |
| XKH001 Injection in Healthy Subjects XKH001 Injection, XKH001 Placebo Injection - Asthma | Phase 1 / Phase 2 | Completed | Beijing Kanova Biopharmaceutical Co., LTD | 24 | 2023-05-12 | 2026-03-05 |
| Evaluate Pharmacokinetics and Safety of Slow Release DHEA Slow Release DHEA - Asthma, Genotype | Phase 1 / Phase 2 | Completed | Indiana University | 18 | 2023-03-03 | 2026-09-02 |
| A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma SHR-1905, placebo - Asthma | Phase 2 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 260 | 2023-01-17 | 2026-10-15 |
| Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. TQC2731 injection, Placebo - Severe Asthma | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 205 | 2022-09-23 | 2025-11-20 |
| Timely Intravenous Magnesium for Asthma in Children Magnesium Sulfate, Heptahydrate, 0.9% saline - Asthma | Phase 2 | Completed | University of Utah | 52 | 2022-09-12 | 2024-12-18 |
| A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma Placebo 152a, Placebo 134a - Asthma | Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 25 | 2022-08-03 | 2024-10-15 |
| Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma ARS-1 1 mg, Albuterol MDI, Placebo - Asthma | Phase 2 | Completed | ARS Pharmaceuticals, Inc. | 18 | 2022-07-28 | 2026-07-14 |
| Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma Amlitelimab, Placebo - Asthma | Phase 2 | Completed | Sanofi | 437 | 2022-06-30 | 2026-03-30 |
Showing 20 of 491. Sign in to see all of them.
Hypersensitivity (22) · Pulmonary Disease, Chronic Obstructive (22) · Inflammation (10) · Lung Diseases (9) · Obesity (9) · Respiratory Sounds (9) · Rhinitis (9) · Rhinitis, Allergic (9) · Respiratory Tract Diseases (8) · Dyspnea (7) · Asthma, Exercise-Induced (6) · Bronchial Diseases (6) · Bronchial Spasm (6) · Respiratory Aspiration (6)
Immune System Diseases (489) · Hypersensitivity, Immediate (487) · Bronchial Diseases (485) · Respiratory Hypersensitivity (485) · Respiratory Tract Diseases (483) · Lung Diseases, Obstructive (478) · Lung Diseases (474) · Hypersensitivity (469) · Pathological Conditions, Signs and Symptoms (69) · Pathologic Processes (42) · Disease Attributes (26) · Nose Diseases (24) · Otorhinolaryngologic Diseases (24) · Chronic Disease (23) · Infections (23)
Formoterol Fumarate (26) · Albuterol (25) · Fluticasone (24) · montelukast (21) · Budesonide (13) · Beclomethasone (12) · Mometasone Furoate (12) · Salmeterol Xinafoate (10) · fluticasone furoate (10) · Omalizumab (9) · Tiotropium Bromide (9) · indacaterol (9) · Fluticasone-Salmeterol Drug Combination (8) · lebrikizumab (7) · 3-(3-tert-butylsulfanyl-1-(4-(6-ethoxypyridin-3-yl)benzyl)-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropionic acid (6)
GlaxoSmithKline (52) · AstraZeneca (29) · Novartis Pharmaceuticals (26) · Chiesi Farmaceutici S.p.A. (22) · Boehringer Ingelheim (20) · Genentech, Inc. (10) · MedImmune LLC (9) · Novartis (9) · Amphastar Pharmaceuticals, Inc. (8) · Sanofi (8) · Teva Branded Pharmaceutical Products R&D, Inc. (8) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Dey (6) · Hoffmann-La Roche (6) · Merck Sharp & Dohme LLC (6)
United States (239) · Germany (104) · United Kingdom (102) · Canada (73) · Poland (68) · Bulgaria (39) · Russia (39) · Hungary (36) · South Africa (35) · Ukraine (35) · France (34) · Argentina (30) · South Korea (29) · Belgium (28) · Mexico (25)
Dave Singh, MD (8) · Paul O'Byrne, MD (4) · Elliot Israel, MD (3) · Louis-Philippe Boulet, MD (3)
PMID 27881132, PMID 36472162, PMID 39393433, PMID 24010736, PMID 24184147, PMID 26001563, PMID 26283085, PMID 26704701, PMID 28758192, PMID 33217063, PMID 33305842, PMID 34089147, PMID 36253275, PMID 11398072, PMID 17950857, PMID 18244953, PMID 18403223, PMID 18699936, PMID 18787222, PMID 19136369, PMID 19196814, PMID 19264687, PMID 19614621, PMID 19656525, PMID 19728196, PMID 19748656, PMID 19821718, PMID 20001651, PMID 20012982, PMID 20056900, PMID 20100026, PMID 20110554, PMID 20193079, PMID 20334686, PMID 20528605, PMID 20545703, PMID 20920778, PMID 21057005, PMID 21060320, PMID 21093024, PMID 21109557, PMID 21356110, PMID 21473764, PMID 21545249, PMID 21584948, PMID 21614939, PMID 21636120, PMID 21762224, PMID 21807250, PMID 21812663
2009 (12), 2014 (7), 2015 (6), 2016 (5), 2008 (4), 2017 (3), 2023 (3), 2019 (2), P01HL158507 (2), 2004 (1), 2018 (1), P50AT002782 (1), R01ES025124 (1), R01HL080073 (1), R01HL088590 (1)